A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 for Healthy Subjects in Fed State
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Lobeglitazone (Primary) ; Lobeglitazone/D745/D150-Chong-Kun-Dang (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 22 Jan 2024 Status changed from recruiting to completed.
- 01 Jun 2023 Status changed from not yet recruiting to recruiting.
- 21 Apr 2023 New trial record